AstraZeneca
rare disease | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
9 of 49
Related slides by other companies
Equillium
Investor Presentation
December 2023
clinically validated in severe dermatological disease | Equillium
Ocuphire Pharma
Results
October 2022
oral treatments in clinical development | Ocuphire Pharma
DICE Therapeutics
Investor Presentation
March 2023
dice pipeline overview | DICE Therapeutics
AN2 Therapeutics
IPO
March 2022
a day phase dose ranging study of oral supports once daily dose for patients with treatment refractory mac lung disease phase design and results mere male placebo generally well tolerated no serious adverse events no severe aes no deaths linear and predictable results support further clinical development of in lung disease data from and other clinical studies combined into population model results used in combination with preclinical data to determine oral dosage for study phase pivotal trial once daily dose achieved high probability of target attainment for treatment of mac lung disease and was well tolerated an therapeutics | AN2 Therapeutics
Other recent decks by AstraZeneca
See all presentations (27 decks)
Results
February 2024
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io